Ori Ben-Yehuda, MD
Cardiovascular Disease · San Diego, CANPI 1508912387
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,250 of the $23,504 with a category attached, or 64.9%. Medtronic accounts for 82.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $22,414 and has fallen 99.4% since, to $137 in 2025.
Across 33 payments — averaging $712.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$19K
- Edwards Lifesciences$3K
- Jenavalve Technology, Inc.$237
- Penumbra, Inc.$235
- Kiniksa Pharmaceuticals, Ltd.$180
- Shockwave Medical, Inc$167
- plus $17 from 1 others
Across 4 payments — averaging $85,290 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$341K
Across 2 payments — averaging $74,999 each. An ownership or investment interest held by the physician or an immediate family member.
- Vektor Medical Inc.$150K
What the payments were for
- Consulting fees$15,25065%
- Travel & lodging$6,72329%
- Food & beverage$1,5317%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 19 | $19,279 |
| Edwards Lifesciences | 6 | $3,390 |
| Jenavalve Technology, Inc. | 3 | $237 |
| Penumbra, Inc. | 1 | $235 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $180 |
| Shockwave Medical, Inc | 1 | $167 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,504 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $125,922 |
| EntrestoSacubitril/Valsartan | 88 | $83,591 |
| JardianceEmpagliflozin | 50 | $60,012 |
| FarxigaDapagliflozin Propanediol | 22 | $27,650 |
| XareltoRivaroxaban | 21 | $13,211 |
| CorlanorIvabradine Hcl | 11 | $9,798 |
| Ezetimibe | 189 | $8,881 |
| Metoprolol Succinate | 122 | $1,709 |
| Verapamil SrVerapamil Hcl | 14 | $1,590 |
| Rosuvastatin Calcium | 63 | $1,542 |
| Losartan Potassium | 92 | $1,425 |
| Atorvastatin Calcium | 107 | $1,347 |
| Eplerenone | 18 | $974 |
| Flecainide Acetate | 27 | $919 |
| Amiodarone Hcl | 55 | $866 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$278K
- Michael WilkinsonSan Diego$145K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.